Professor Nigel Lovell
Professor Nigel Lovell FTSE Scientia Professor
Scientia Prof Nigel Lovell is the Head of the Graduate School of Biomedical Engineering at UNSW Sydney and Director of the Tyree Institute of Health Engineering (IHealthE). He is a Fellow of eight learned academies internationally. For his contributions in biomedical engineering, in 2000 he was awarded the prestigious IEEE Millennium medal. For 2017-2018 he was President of the IEEE EMBS (world's largest biomedical engineering professional society). Prof Lovell's research and development work has covered areas of expertise ranging from cardiovascular physiology and neural prosthesis to web-enabling technologies. He is a world recognised expert in telehealth systems, and predictive analytics for managing disease and wellness. His principal research interests have been focused on the application of appropriate technology in primary health care for managing disease burden, the creation of a retinal neuroprosthesis or bionic eye, and design of wearable fall monitoring technology for falls detection and prevention. He has published >680 journal articles [h-index=73, cited 26,800] and conference papers (Elsevier SciVal has ranked him top ten most published in biomedical engineering worldwide). He has been awarded >$115 million in research funding. In addition to relevant research skills, he has been involved in translational R&D for over two decades including in 2001 co-founding a telehealth startup company that gained regulatory approval for a range of medical devices for managing chronic disease (TGA/FDA/CE and implementing QMS under ISO13485).

Fellow status Elected 2011 Division NSW Forum(s) Health Technology
Fellowship Affiliations The University of New South Wales (UNSW) Classification Academia Sector Expertise 262 - Medical technology, 411 - Research and development, 451 - Interface of technology and society

Biography at time of election

For outstanding contributions to the biomedical profession and the wider community through research,
development, commercialisation and international clinical trialling of medical devices including world leading
telehealth systems for managing chronic disease and retinal neuroprostheses for the vision impaired.